Shots: Immatics to get $75M up front and is also eligible to receive ~$505M as option exercise fee for each licensed product including development, regulatory & commercial milestone plus royalties […]readmore
Tags : Multiple Cancers
Shots: Presage utilizes its CIVO intratumoral microdosing platform to evaluate Celgene’s early stage products in P-0 trial The collaboration follows safety & feasibility of CIVO in sarcoma patients, a clinical […]readmore